Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Interoperability as 2020 Dawns

The ability for the health care industry to effectively utilize separate information systems in a way that integrates those systems and allows for the exchange and cooperative use of critical data, is more important than ever, and interoperability will only continue to gain momentum as we move into 2020 and beyond. With that in mind,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The ability for the health care industry to effectively utilize separate information systems in a way that integrates those systems and allows for the exchange and cooperative use of critical data, is more important than ever, and interoperability will only continue to gain momentum as we move into 2020 and beyond.

With that in mind, let’s dive into where interoperability stands, today, and where it might be headed.

Interoperability Today

There are four levels of interoperability – foundational, structural, semantic and organizational1.

Foundational refers to the ability of one system to communicated with another, while structural “defines the format, syntax and organization of data exchange.” Semantic helps tie data together in a way that provides common meaning and understanding to data, and organizational refers to ways the health care industry, the government, and more are working to provide considerations and standards surrounding interoperability.

While interoperability is, in theory, the future of patient care and patient-data transfer, a survey conducted by the Office of the National Coordinator for Health Information Technology (ONC) found that in both 2015 and 2017, only about 10% of physicians “engaged in all four domains of interoperability” – send, receive, find and integrate.

The same survey suggested that the small percentage of physicians who do participate in all four domains are more likely to have patient info available electronically from outside sources, providing a glimpse into the benefits of adopting full interoperability.

Currently, the Interoperability Standards Advisory process is the ONC’s main way of attempting to spur the industry toward dialogue about “the identification, assessment, and public awareness of interoperability standards and implementation specifications” and of addressing key needs surrounding interoperability.

While interoperability is growing, obstacles still exist in the form of non-standardized patient information, changing payment incentives, confusion surrounding privacy laws and hesitance regarding the security of data exchange.

Looking to 2020 and Beyond

It’s clear that increased interoperability is needed in the health care industry – lower costs, better care, increased efficiency and more will almost certainly result from interoperability’s continued growth.

To get there, however, the industry will need to consider four pillars of interoperability2:

Patient Directed

New regulations like the 21st Century Cares Act are aimed at increasing patient access to their own data, and creating more informed and cared-for patients is the ultimate goal. However, if providers aren’t prepared and knowledgeable about how to comply with these standards, they could be in for a nasty surprise in the form of penalties. Entering 2020, it’s critical that providers looking to increase interoperability are aware of the steps they’ll need to take to do it the right way and with a patient-focused mindset.

Patient Data Access

As patients receive more access to their data, it’s critical that modern forms of providing that access are considered. Moving into 2020, patients will look to be able to access their records in a variety of ways, including in real-time using their smartphones. Security also needs to be a key consideration – while patients will relish this ease of access, they could also be hindered or turned away completely if they don’t feel the process is airtight.

Shared Records

The Statewide Health Information Network for New York is a tremendous example of the kind of shared access needed around the country – when care providers have quick and thorough access to patient information as part of a network like SHIN-NY, they’re empowered to make faster and more complete decisions for patients. It’s important, then, that the industry continues to push for the creation of more organizations like SHIN-NY.

EHR-to-EHR

While EHR-to-EHR communication is the most common of the four pillars, this communication is often still lagging behind. Internal EHR capabilities are getting votes of confidence around the country, but the sharing of data between parties is still limping along. In fact, according to a survey conducted by the Center for Connected Medicine (CCM), only 37% of respondents said they “can successfully share information with other health systems.”

Sources:

  1. https://www.himss.org/what-interoperability
  2. https://ehrintelligence.com/news/4-interoperability-pillars-driving-data-access-outcomes-in-2020

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512